Syed Yousuf Zafar, MD

Associate Professor of Medicine
Associate Professor in the Sanford School of Public Policy
Associate Professor in Population Health Sciences
Affiliate, Duke Global Health Institute
Core Faculty Member, Duke-Margolis Center for Health Policy
Associate of the Duke Initiative for Science & Society
Member of the Duke Cancer Institute
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3505, Durham, NC 27710
Phone (919) 684-8111
Email address yousuf.zafar@duke.edu

Dr. Zafar is a gastrointestinal medical oncologist and Associate Professor of Medicine, Public Policy, and Population Health Science at the Duke Cancer Institute and Duke-Margolis Center for Health Policy. He serves as Director of Healthcare Innovation at the Duke Cancer Institute. Dr. Zafar also serves as Clinical Associate Director of Duke Forge (Health Data Science Center). Dr. Zafar is considered an international expert in identifying and intervening upon the financial burden of cancer care. His research explores ways to improve cancer care delivery with a primary focus on improving the value of cancer treatment from both patient-focused and policy perspectives.

Dr. Zafar speaks internationally on his research and cancer care delivery. He has over 100 publications in top peer-reviewed journals including the New England Journal of Medicine, the Journal of Clinical Oncology, and JAMA Oncology. His research has been funded by the National Institutes of Health and the American Cancer Society, among others. His work has been covered by national media outlets including New York Times, Forbes, Wall Street Journal, NPR, and Washington Post. He is a Fellow of the American Society of Clinical Oncology.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2008
  • Resident, Medicine, University of Cincinnati, 2002 - 2005
  • M.D., The University of Toledo, 2002

Publications

Moss, Haley A., Jenny Wu, Samantha J. Kaplan, and S Yousuf Zafar. “The Affordable Care Act's Medicaid Expansion and Impact Along the Cancer-Care Continuum: A Systematic Review.” J Natl Cancer Inst 112, no. 8 (August 1, 2020): 779–91. https://doi.org/10.1093/jnci/djaa043.

PMID
32277814
Full Text

Lou, Emil, Muhammad Shaalan Beg, Emily Bergsland, Cathy Eng, Alok A. Khorana, Scott Kopetz, Sam Lubner, Leonard Saltz, Veena Shankaran, and S Yousuf Zafar. “Reply to S. Boutayeb et al.” Jco Oncol Pract 16, no. 8 (August 2020): 525. https://doi.org/10.1200/OP.20.00394.

PMID
32574129
Full Text

Lou, Emil, Shaalan Beg, Emily Bergsland, Cathy Eng, Alok Khorana, Scott Kopetz, Sam Lubner, Leonard Saltz, Veena Shankaran, and S Yousuf Zafar. “Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.” Jco Oncol Pract 16, no. 7 (July 2020): 383–88. https://doi.org/10.1200/OP.20.00239.

PMID
32352884
Full Text

Khera, Nandita, Jessica Sugalski, Diana Krause, Richard Butterfield, Nan Zhang, F Marc Stewart, Robert W. Carlson, Joan M. Griffin, S Yousuf Zafar, and Stephanie J. Lee. “Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions.” J Natl Compr Canc Netw 18, no. 7 (July 2020): 825–31. https://doi.org/10.6004/jnccn.2020.7538.

PMID
32634772
Full Text

Langer, Shelby, Michael Todd, Joan M. Romano, Niall Bolger, Jonathan Bricker, Karen L. Syrjala, John Burns, et al. “THE RELATIONSHIP INTIMACY MODEL OF COUPLE ADAPTATION TO CANCER: SUPPORT FROM A PROSPECTIVE, LONGITUDINAL, SMARTPHONE-ENABLED ECOLOGICAL MOMENTARY ASSESSMENT STUDY.” In Annals of Behavioral Medicine, 54:S142–S142, 2020.

Scholars@Duke

Tran, George, Matthew Harker, Karen Chiswell, Joseph M. Unger, Mark E. Fleury, Bradford Hirsch, Kimberly Miller, Philip d’Almada, Sheri Tibbs, and S Yousuf Zafar. “Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence.” Jco Clin Cancer Inform 4 (January 2020): 35–49. https://doi.org/10.1200/CCI.19.00088.

PMID
31977253
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Greenup, Rachel A., Christel N. Rushing, Laura J. Fish, Whitney O. Lane, Jeffrey M. Peppercorn, Emily Bellavance, Lisa Tolnitch, et al. “Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons.” In Ann Surg Oncol, 26:3141–51, 2019. https://doi.org/10.1245/s10434-019-07594-3.

PMID
31342390
Full Text

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.

PMID
31444620
Full Text

Pages